CY1117021T1 - Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης - Google Patents

Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης

Info

Publication number
CY1117021T1
CY1117021T1 CY20151101150T CY151101150T CY1117021T1 CY 1117021 T1 CY1117021 T1 CY 1117021T1 CY 20151101150 T CY20151101150 T CY 20151101150T CY 151101150 T CY151101150 T CY 151101150T CY 1117021 T1 CY1117021 T1 CY 1117021T1
Authority
CY
Cyprus
Prior art keywords
salt
nilotinibe
pharmaceutical compositions
compositions containing
granules
Prior art date
Application number
CY20151101150T
Other languages
English (en)
Inventor
Nathalie Bruneau
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117021(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1117021T1 publication Critical patent/CY1117021T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Μία φαρμακευτική σύνθεση, ειδικότερα κάψουλες, η οποία περιέχει κοκκία τα οποία περιέχουν νιλοτινίβη ή ένα άλας αυτής, με τουλάχιστον ένα φαρμακευτικά αποδεκτό έκδοχο. Τα κοκκία μπορούν να παράγονται δια μίας υγρής μεθόδου κοκκιοποίησης.
CY20151101150T 2006-09-27 2015-12-16 Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης CY1117021T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06121371A EP1923053A1 (en) 2006-09-27 2006-09-27 Pharmaceutical compositions comprising nilotinib or its salt
EP07820560.6A EP2068839B2 (en) 2006-09-27 2007-09-25 Pharmaceutical compositions comprising nilotinib or its salt

Publications (1)

Publication Number Publication Date
CY1117021T1 true CY1117021T1 (el) 2017-04-05

Family

ID=37684496

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20151101150T CY1117021T1 (el) 2006-09-27 2015-12-16 Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης
CY20231100367T CY1126116T1 (el) 2006-09-27 2023-07-27 Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20231100367T CY1126116T1 (el) 2006-09-27 2023-07-27 Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη

Country Status (35)

Country Link
US (2) US8293756B2 (el)
EP (4) EP1923053A1 (el)
JP (2) JP5567340B2 (el)
KR (2) KR20090076931A (el)
CN (2) CN101516344A (el)
AR (1) AR062980A1 (el)
AU (1) AU2007301977B2 (el)
BR (1) BRPI0719438B1 (el)
CA (1) CA2662571C (el)
CL (1) CL2007002766A1 (el)
CO (1) CO6160288A2 (el)
CY (2) CY1117021T1 (el)
DK (2) DK3984528T3 (el)
ES (3) ES2957912T3 (el)
FI (2) FI2068839T4 (el)
HK (1) HK1133193A1 (el)
HR (2) HRP20230753T3 (el)
HU (2) HUE028204T2 (el)
IL (1) IL197496A (el)
JO (1) JO3757B1 (el)
LT (1) LT3984528T (el)
MA (1) MA30807B1 (el)
MX (1) MX2009003184A (el)
MY (1) MY148237A (el)
NO (2) NO347404B1 (el)
NZ (1) NZ575317A (el)
PE (2) PE20081379A1 (el)
PL (2) PL3984528T3 (el)
PT (2) PT3984528T (el)
RU (1) RU2469707C2 (el)
SI (2) SI3984528T1 (el)
TN (1) TN2009000093A1 (el)
TW (3) TW201418245A (el)
WO (1) WO2008037716A2 (el)
ZA (1) ZA200901511B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CA2775400A1 (en) 2009-09-28 2011-03-31 Medizinische Universitat Wien New use of pdgfrbeta inhibitors
EP2490690A1 (en) * 2009-10-23 2012-08-29 Novartis AG Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib
AR086913A1 (es) * 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
CN102321073A (zh) * 2011-08-12 2012-01-18 西安交通大学 一种尼罗替尼的制备方法
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140096035A (ko) 2011-10-28 2014-08-04 노파르티스 아게 위장 기질 종양을 치료하는 방법
US9301957B2 (en) 2011-11-14 2016-04-05 Novartis Ag Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
JP6275645B2 (ja) * 2011-11-14 2018-02-07 ノバルティス アーゲー ４−メチル−３−［［４−（３−ピリジニル）−２−ピリミジニル］アミノ］−ｎ−［５−（４−メチル−１ｈ−イミダゾール−１−イル）−３−（トリフルオロメチル）フェニル］ベンズアミドの即放性製剤
EP2872142A1 (en) 2012-07-11 2015-05-20 Novartis AG Method of treating gastrointestinal stromal tumors
WO2014174496A1 (en) 2013-04-25 2014-10-30 Ranbaxy Laboratories Limited Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
LT3189045T (lt) * 2014-08-11 2022-04-11 Sun Pharmaceutical Industries Limited Naujos nilotinibo druskos ir jų polimorfai
US10045987B2 (en) * 2014-08-28 2018-08-14 Codexis, Inc. Imidazoyl anilide derivatives and methods of use
EP3429589B1 (en) * 2016-03-17 2022-12-14 Sun Pharmaceutical Industries Ltd Pharmaceutical composition of nilotinib
CN107582531B (zh) * 2016-07-06 2020-12-29 四川科伦药物研究院有限公司 一种利伐沙班固体制剂及其制备方法
CN107320460B (zh) * 2017-08-04 2020-11-03 北京化工大学 一种尼罗替尼口服纳米制剂及其制备方法
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI815137B (zh) 2018-06-15 2023-09-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽之結晶
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
CA3224750A1 (en) 2021-06-19 2022-12-22 Helm Ag Granulate composition comprising nilotinib
WO2023285981A1 (en) * 2021-07-15 2023-01-19 Torrent Pharmaceuticals Limited Stable pharmaceutical liquid composition of nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072535A (en) * 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP3125221B2 (ja) * 1990-09-01 2001-01-15 大正製薬株式会社 ソファルコン含有固形製剤
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
SK9199A3 (en) 1996-07-24 1999-07-12 Celgene Corp 2,6-dioxopiperidines, pharmaceutical composition them containing and their use
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
EA004872B1 (ru) 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
CN1679556A (zh) * 1999-12-08 2005-10-12 法马西亚公司 维得克西组合物
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CN1674877A (zh) * 2002-06-07 2005-09-28 兰贝克赛实验室有限公司 控释的多单位药物释放系统
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ES2379075T3 (es) * 2002-11-26 2012-04-20 Universiteit Gent Proceso y aparato para granulación húmeda continua de material en polvo
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
JP2007501218A (ja) * 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
TR200301553A1 (tr) 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
WO2006013444A1 (en) 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation
WO2006038552A1 (ja) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. 微粒子含有組成物およびその製造方法
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
DK1843771T3 (da) * 2005-01-28 2012-01-16 Novartis Ag Anvendelse af pyrimidylaminobenzamider til behandling af sygdomme, der responderer på modulation af Tie-2-kinase-aktiviteten
MX2007011866A (es) * 2005-02-25 2007-10-10 Novartis Ag Combinacion farmaceutica de inhibidores de bcr-abl y raf.
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CN101516339B (zh) * 2006-08-16 2012-06-13 诺瓦提斯公司 制备高度结晶的治疗化合物的固体分散体的方法
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt

Also Published As

Publication number Publication date
IL197496A (en) 2016-04-21
HRP20151383T4 (hr) 2023-03-03
US20130023549A1 (en) 2013-01-24
EP3984528A1 (en) 2022-04-20
SI3984528T1 (sl) 2023-09-29
DK2068839T3 (da) 2016-01-11
BRPI0719438B1 (pt) 2022-04-19
CY1126116T1 (el) 2023-11-15
MY148237A (en) 2013-03-29
BRPI0719438A2 (pt) 2013-12-10
ES2957912T3 (es) 2024-01-29
EP3009128A1 (en) 2016-04-20
JO3757B1 (ar) 2021-01-31
ES2556625T5 (es) 2023-03-02
EP2068839B2 (en) 2022-10-12
JP2010504942A (ja) 2010-02-18
AU2007301977B2 (en) 2011-09-08
SI2068839T2 (sl) 2023-01-31
CA2662571A1 (en) 2008-04-03
LT3984528T (lt) 2023-08-10
RU2469707C2 (ru) 2012-12-20
FI2068839T4 (fi) 2023-01-31
HUE063083T2 (hu) 2023-12-28
KR20140121903A (ko) 2014-10-16
CA2662571C (en) 2016-09-27
NO20220946A1 (no) 2009-04-24
AU2007301977A1 (en) 2008-04-03
CO6160288A2 (es) 2010-05-20
KR101598747B1 (ko) 2016-03-02
PL3984528T3 (pl) 2023-08-28
EP2068839A2 (en) 2009-06-17
RU2009115782A (ru) 2010-11-10
MA30807B1 (fr) 2009-10-01
CN104306350A (zh) 2015-01-28
ES2556625T3 (es) 2016-01-19
TW200821298A (en) 2008-05-16
HRP20151383T1 (hr) 2016-01-15
ZA200901511B (en) 2010-02-24
US20100087463A1 (en) 2010-04-08
NO20091501L (no) 2009-04-24
PE20081379A1 (es) 2008-11-27
JP5567340B2 (ja) 2014-08-06
HUE028204T2 (en) 2016-12-28
CL2007002766A1 (es) 2008-08-08
TWI540128B (zh) 2016-07-01
IL197496A0 (en) 2009-12-24
US8501760B2 (en) 2013-08-06
KR20090076931A (ko) 2009-07-13
ES2951547T3 (es) 2023-10-23
TWI428333B (zh) 2014-03-01
EP2068839B1 (en) 2015-09-23
TW201418245A (zh) 2014-05-16
PL2068839T3 (pl) 2016-06-30
MX2009003184A (es) 2009-04-03
PT2068839E (pt) 2015-12-30
EP1923053A1 (en) 2008-05-21
WO2008037716A3 (en) 2008-07-17
NO346639B1 (no) 2022-11-07
PT3984528T (pt) 2023-08-07
EP3984528B1 (en) 2023-07-05
JP2014065715A (ja) 2014-04-17
NZ575317A (en) 2011-12-22
AR062980A1 (es) 2008-12-17
DK3984528T3 (da) 2023-07-31
HK1133193A1 (en) 2010-03-19
EP3009128B1 (en) 2023-07-05
TN2009000093A1 (en) 2010-08-19
US8293756B2 (en) 2012-10-23
HRP20230753T3 (hr) 2023-10-27
PE20120626A1 (es) 2012-06-07
NO347404B1 (no) 2023-10-16
SI2068839T1 (sl) 2016-02-29
TW201418244A (zh) 2014-05-16
WO2008037716A2 (en) 2008-04-03
FI3984528T3 (fi) 2023-07-27
CN101516344A (zh) 2009-08-26
PL2068839T5 (pl) 2023-01-30

Similar Documents

Publication Publication Date Title
CY1117021T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν νιλοτινιβη ή αλας αυτης
BRPI0810646A2 (pt) " compostos farmacêuticos ".
DK1863526T3 (da) Levende, attenueret rotavirusvaccine til oral indgivelse
PT1808164E (pt) Método de granulação húmida para a preparação de composições farmacêuticas de aripiprazole
UA90875C2 (ru) Лекарственные формы пролонгированного действия, которые содержат ранолазин
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
BRPI0719398A2 (pt) Composição farmacêutica.
AP2384A (en) 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them.
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
EP1916251A4 (en) ERIANINE SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EA201300990A1 (ru) Парентеральное введение тапентадола
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
WO2006134021A3 (en) Process for preparing tiotropium salts, tiotropium salts as such and pharmaceutical compositions thereof
WO2009022327A3 (en) Novel process for preparing highly pure levocetirizine and salts thereof
ZA200803152B (en) Oramucosal pharmaceutical dosage form
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
BRPI0610156A2 (pt) forma micronizada de um composto, forma purificada i do composto, kit, padrão de referência, e, método de preparaçao de uma composição farmacêutica.
BRPI0815562A2 (pt) Soluções farmacêuticas orais contendo telbivudina.
WO2007071444A3 (en) Esomeprazole arginine
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
EP1850829A4 (en) NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS
DE602006008339D1 (en) Zolpidemtabletten
BRPI0811431A2 (pt) Composição farmacêutica aquosa.